NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.89 -0.11 (-0.14%) GOLD FUTURES
2,315.00 +4.00 (+0.17%) DOW
38,194.83 +291.54 (+0.77%) Bitcoin GBP
47,154.24 +927.62 (+2.01%)
WBA Jan 2025 42.500 call
| Previous close | 0.0800 |
| Open | 0.1000 |
| Bid | 0.0100 |
| Ask | 0.0700 |
| Strike | 42.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 7.44k |
Yahoo FinanceWalgreens partners with Boehringer Ingelheim for clinical trials
Walgreens is ramping up its clinical trial offerings with Big Pharma players.
Business WireWalgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
DEERFIELD, Ill. & RIDGEFIELD, Conn., May 02, 2024--Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and r
BenzingaInvestor Optimism Dampens as Walgreens Boots Alliance Struggles With Market Turbulence
Walgreens Boots Alliance Inc. (NASDAQ:WBA) is facing tumultuous times as it grapples with a challenging turnaround, leading to a drastic decline in its stock value, marking its worst performance in over five years. The company’s shares plummeted by 18% in April, nearing a 26-year low, following a downward revision of its outlook. This revision was accompanied by concerns over decreased consumer spending and the revelation of a substantial unpaid tax liability amounting to $2.7 billion, adding to
